



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Powell et al.
SERIAL NUMBER: 09/766,863 EXAMINER: Not Yet Assigned
FILING DATE: January 19, 2001 ART UNIT: 1645
FOR: METHOD OF IDENTIFYING THE FUNCTION OF A TEST AGENT

**STATEMENT IN SUPPORT OF SUBSTITUTE SPECIFICATION
(37 CFR 1.125(b)(1))**

Pursuant to 37 CFR 1.125(b)(1), I hereby state that the content of the substitute specification and the specification filed on January 19, 2001 are the same. Applicants hereby submit this substitute specification in response to the Notice to File Missing Parts mailed on February 27, 2001, which specifically requested a substitute specification in compliance with 37 CFR 1.52. The correction of the margins is the only amendment made to the specification at this time. Thus, this submission includes no new matter.

Applicants believe that no fee is required for the filing of the present submission. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment, to Deposit Account No. 50-0311, Ref. No.15966-641 (CURA-141).

Respectfully submitted,

Dated: June 18, 2001

Ivor R. Elrifi, Reg. No. 39,829
Kristin E. Konzak, Reg. No. 44,848
Attorney/Agent for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241



METHOD OF IDENTIFYING THE FUNCTION OF A TEST AGENT

RELATED APPLICATIONS

This application claims priority to USSN 60/177,416, filed January 21, 2000. The contents of this application are incorporated herein by reference in their entirety.

5

FIELD OF THE INVENTION

The invention relates to biochemistry, molecular biology, and cell biology.

BACKGROUND OF THE INVENTION

The accumulation of raw nucleic acid sequence information for various organisms, coupled with the development of methods for identifying open reading frames encoding candidate proteins, is creating a need for methods that determine the function of previously unknown proteins. To date, functions of unknown proteins can be inferred by identifying genes whose expression changes (by increasing or decreasing) in the presence of the agent protein. However, such gene expression assays can be costly and labor-intensive. An effective and economical method for screening novel proteins for functions of interest is needed in the art.

SUMMARY OF THE INVENTION

The invention is based in part on the discovery of a system and method for rapidly and economically identifying the function of a test agent, such as a polypeptide, by examining changes in expression of genes in a plurality of cells contacted with the test agent.

In one aspect, the invention includes a method of identifying the function of a test compound by contacting a plurality of cells with a test compound. The plurality includes at least a first cell and a second cell of a different type than the first cell type. Expression of one or more genes in cells or the plurality is measured. An alteration in the expression of the genes relative to the expression genes in a reference cell reveals the function of the test compound. For example,

if the test compound is a polypeptide and induces a gene expression pattern characteristic of a cytokine, the test compound is considered a candidate new cytokine.

Preferably, the plurality includes three, four, five, six, or ten or more distinct cell types. Preferably, the expression of multiple genes, *e.g.*, at least two, three, four, five, seven, and even ten genes is measured in one or more of the distinct cells in the array.

For example, the method can include measuring the expression of at least two genes (and more preferably at least five genes) in the first cell, and, optionally measuring the expression of at least two genes (and more preferably at least five genes) in the second cell. In a preferred embodiment, expression of one or more genes is also measured in a third cell, wherein the third cell is a different cell type from the first cell and the second cell. In a more preferred embodiment, expression of one or more genes is also measured in a fourth cell, wherein the fourth cell is a different cell type from the first cell, the second cell type, and the third cell type.

Expression of a gene or genes in a cell exposed to a test agent can be compared to expression of the gene in a reference cell (*e.g.*, otherwise identical cells not exposed to the test agent). The reference cell may be processed in parallel to cells in the plurality; alternatively, expression information for the reference cell can be stored in a database.

The plurality of cells is preferably provided in a container in which different cell types in the plurality are spatially segregated. A preferred container is one in which the test agent can be added to the cells, after which the cells are lysed for isolating RNA. The container may in addition include control cells, *e.g.*, cells not exposed to a test agent.

Examples of suitable test compounds include small molecules (typically molecules with molecular weights less than 1000 kDa) or larger macromolecules such as polynucleotides (including ribozymes) and polypeptides. Suitable polypeptides can also include antibodies. In some embodiments, two or more test compounds are added to the plurality of cells.

While any kind of cell can be used in the method, preferred cells are mammalian (*e.g.*, human) cells. Cells can be from established cell lines, or can be primary cells. Cell lines used in the method are preferably derived from multiple tissue types. Cell lines may be growth factor dependent or growth factor independent. Test compounds may be added in the presence or absence of serum. Cell lines may be derived from tissues of different species, but are preferably mammalian cells. Most preferably, the cells are derived from human cells. The cell can be

derived from a human tissue, *i.e.*, a primary cell, or can be from an established (*e.g.*, immortalized) cell line.

Examples of cells suitable for use in the invention include MG-63 cells, U87-MG cells, TF-1 cells, HepG2 cells, THP-1 cells, HUVEC cells, CCD-1070SK cells, and Jurkat E6-1 cells.

5 In some embodiments, a cell line of the invention is associated with a clinical indication, disorder or disease.

Any method known in the art can be used to measure gene expression. A preferred method is polymerase chain reaction, *e.g.*, real-time polymerase chain reaction.

Also provided by the invention is a method of identifying the function of a test
10 polypeptide by contacting a plurality of cells with the test polypeptide. The plurality includes a first mammalian cell, a second mammalian cell, and a third mammalian cell, wherein the first cell is a different cell type from the second cell type, the second cell type is a different cell type from the third cell type, and the third cell type is a different cell type from the first cell type. Expression of three or more genes is measured in the first cell, second cell, and third cell. An alteration in the level of expression of the gene relative to the expression of the genes in a reference cell indicates the function of the test compound. Expression is preferably measured using a polymerase chain reaction, *e.g.*, a real-time polymerase chain reaction.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention
20 belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are
25 illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

DETAILED DESCRIPTION OF THE INVENTION

30 The invention provides a method for rapidly and economically identifying the function of a test agent of interest by adding the test agent to multiple cell lines, and measuring changes in

gene expression of a predetermined set of genes in each cell line. By identifying those genes whose expression changes in the presence of the test agent as compared to the expression of the gene in the absence of the agent, it is possible to make inferences about the function of the polypeptide. The screen can be performed prior to, or contemporaneous with, other cell-based assays. These assays include assays measuring cell growth (bromodeoxyuridine ("BrdU") incorporation or the colorimetric 3-(4,5)-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide ("MTT") metabolism assay).

Cell lines and genes examined are preferably chosen so that information on changes in gene expression in a cell will provide insight into the function of the polypeptide. Examples of cells and corresponding genes suitable for use in the methods in the invention are described in Table 1. Genes for which changes in expression are associated with biological functions and relevant clinical indications are provided in Table 2. Examples of additional cells include, *e.g.*, T Cells, monocytes, B Cells, NK Cells, normal human osteoblasts (NHOst), astrocytes, hepatocytes, and normal human lung fibroblasts. Additional genes to test for induced changes in expression are CD23, IFN γ , TNF α , and GCSF.

Screening is conveniently performed in a container in which it is possible to culture cells, add the test agent, and lyse cells for RNA isolation. The container segregates different cell types and can in addition include control cells (*e.g.*, cells not exposed to agent). For cells whose growth is serum-dependent, the container may additionally include cells exposed to a test agent but not serum.

A preferred container is a 96-well plate. A single well of a 96-well plate generates sufficient RNA for at least 12 PCR tests, thus allowing for the probing of 11 diagnostic genes plus a negative control (where the negative control may be, for example, GAPDH minus RT) per cell line. Additionally, expression of a reference gene can be monitored in each well and serve as an internal control or standard. An example of such a reference gene is GAPDH. PCR plate layouts and cell culture techniques are commonly known within the art. Cell lysates can then be transferred to a second container, if desired, in which RNA is isolated and further manipulations (such as PCR-based analyses) performed.

Genes whose expression is to be measured are preferably chosen for each cell line to provide detection of a broad spectrum of desired biological activities, *e.g.*, a cytokine-like activity in multiple cell types. A test compound that regulates the expression of at least one gene

in at least one cell type by a factor considered to represent a significant change in the level of expression is chosen for further analysis. In one embodiment, the factor of significant change is at least ± 4 -fold.

The invention will be further illustrated in the following non-limiting examples.

5

EXAMPLES

Example 1: Procedure for assessing polypeptide-mediated changes in gene expression in a plurality of cell types.

10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
200
210
220
230
240
250
260
270
280
290
300
310
320
330
340
350
360
370
380
390
400
410
420
430
440
450
460
470
480
490
500
510
520
530
540
550
560
570
580
590
600
610
620
630
640
650
660
670
680
690
700
710
720
730
740
750
760
770
780
790
800
810
820
830
840
850
860
870
880
890
900
910
920
930
940
950
960
970
980
990
1000

On Day 1, adherent cells are plated in a 96-well flat bottom dish in 100 μ l growth medium (2×10^4 to 3×10^4 cells/well). On Day 2, adherent cells are washed with starvation medium and 100 μ l starvation medium is added. Starvation medium contains 0.1% FBS for factor-independent cell lines (*e.g.*, MG-63, U87-MG, HepG2, CCD-1070SK), or 2% FBS minus growth factors for factor-dependent cell lines (*e.g.*, HUVEC). Suspension cells are plated in a 96-well round bottom dish in 100 μ l starvation medium (1×10^5 cells/well). Starvation medium contains 0.1% FBS for factor-independent cell lines (*e.g.*, THP-1, Jurkat), and 10% FBS minus growth factors for factor-dependent cell lines (*e.g.*, TF-1). All cells are incubated for 24 hours.

On Day 3, test compounds are added to the cells. Typically, 10 μ l/well of a 10X stock for known proteins can be added. Alternatively, 10 to 100 μ l/well of undiluted conditioned media for novel proteins may be used. Cells are incubated for 6 hr at 37°C. Cytoplasmic RNA is prepared from cells by centrifuging round-bottom plates containing suspension cells and discarding the supernatant. Supernatant from the flat-bottom wells containing adherent cells is also aspirated and discarded.

RLN lysis buffer is added to all sample wells. Plates are centrifuged, and the lysates (supernatants) are transferred to Uneasy columns (96 column plate). RNA is washed and eluted in 160 μ l RNase free water according to the manufacturer's instructions.

On Day 4, 5, and 8, up to three plates of RNA samples are processed for TaqMan™ expression analysis. A master mix is prepared for each well as follows:

10X TaqMan buffer (provided by the manufacturer)	2.5 μ l
MgCl ₂ 25 mM stock	5.5 μ l

	dNTP	2.5 mM – 5.0 mM stock	3.0 µl
	AmpliTaq Gold	5 U/ml	0.125 µl
	Multiscribe RT	50 U/ml	0.125 µl
	RNAse inhibitor		1.0 µl
5	Forward primer	GAPDH, 10 µM stock	0.5 µl
	Reverse primer	GAPDH, 10 µM stock	0.5 µl
	Probe *	GAPDH, 5 µM stock	0.5 µl
	Forward primer	gene, 45 µM stock	0.5 µl
	Reverse primer	gene, 45 µM stock	0.5 µl
10	Probe *	gene, 22.5 µM stock	0.5 µl
	dH ₂ O		2.25 µl
	Total		17.50 µl

The GAPDH or other selected reference probe is labeled according to a standard TaqMan™ protocol, *e.g.*, 5' ends are labeled with JOE, 3' ends with TAMRA; while the gene-specific probes are labeled with a compound that may be monitored independently of the reference probe, *e.g.*, 5' ends with FAM, 3' ends with TAMRA.

For the TaqMan™ analysis, 17.5 µl per well of the master mix is added to 96 well PCR plates containing 7.5 µl RNA sample per well. Reaction conditions include 2 minutes at 50°C, 10 minutes at 95°C, and 40 cycles of: 1 minute at 95°C, 0.40 minutes at 58°C, 1 minute at 72°C. Amplification is monitored by measuring the release of the fluorescent JOE and FAM markers during the 72°C extension step.

Data are analyzed by comparing expression of each gene to GAPDH. To calculate changes in gene expression, gene expression in control samples is calculated and compared to the equivalent gene expression levels in the test compound-stimulated samples.

Table 1. Cell lines and gene lists for expression analysis.

Cell Line, Tissue Type	Gene List			
MG-63, Osteosarcoma	IRF-1* OPG BMP-3	IL-8* Factor B* MxA*	TAP-1* Collagen** PCNA	LOX* Collagenase
U-87MG, Astrocytoma	IRF-1*** c-Kit c-Myc	IL-8* HLA-DR VEGF	MCP-1* iNOS GDNF	ICAM-1 Tenascin-c*
TF-1, Erythroleukemia	IRF-1*** c-Kit GBP-2	beta-globin Factor B STAT-1	EpoR GpIIb PCNA	ICAM-1**** c-Mpl
HepG2, Hepatoma	IRF-1 c-Kit HMGC CoA Rd	Haptoglobin CYP4A1 Hexokinase	PEPCK Factor X ApoC3	IGFBP1 CYP7A
THP-1, Monocytic	IRF-1 CCR2 TGF-beta1	Egr1 HLA-DR MnSOD	TAP-1 iNOS IL-10	ICAM-1 IL-12
HUVEC, Endothelial	PECAM Tissue Factor KDR	Egr1 COX-2 IL-6	VCAM eNOS MMP-2	ICAM-1 Endothelin-1
CCD-1070SK, Fibroblast	c-Myc c-Kit HMGC CoA Rd	IL-8 COX-2 Hexokinase	FGF-2 Factor III PCNA	FGF-7 Endothelin-1
Jurkat E6-1, T-cell	IL-2 CD69 Bcl-2	IL-3 COX-2 LFA-1	IL-4 NFAT PCNA	IL-2 R Fas Ligand

Highlighted genes were confirmed by GeneCalling on the indicated cell lines:

* = up in IL-1 α treatment

** = up in OPG treatment, down in thrombopoietin treatment

*** = up in IFN γ treatment

**** = up in IL-6 treatment

Remaining genes were selected based on TaqMan results and literature surveys.

Table 2. Functional classification of gene probes.

Functional classifications:	Clinical indications:	Gene List		
Angiogenesis wound healing	Cancer	PECAM	VCAM	COX-2
	Surgical and burn wound healing	Endothelin-1	Tissue Factor	eNOS
		KDR	MMP-2	IL-8
	Gastric ulceration	FGF-2	FGF-7	VEGF
Inflammation	Rheumatoid arthritis	IRF-1	ICAM-1	MCP-1
	Crohn's disease	HLA-DR	iNOS	Factor B
	Multiple sclerosis	GBP-2	Haptoglobin	TAP-1
		CCR2	IL-12	TGF-beta1
		IL-10	MnSOD	IL-6

Metabolism	Obesity NIDDM Cholesterol disorders	CYP4A1 CYP7A MxA	IGFBP1 HMGC _o A Rd Hexokinase	PEPCK ApoC3
Coagulation	Thrombocytopenia Hemophilia	Factor X	Factor III	
T-cell activation	Immune deficiency Cancer immunotherapy Autoimmunity	IL-2 IL-2 R LFA-1	IL-3 NFAT	IL-4 CD69
Bone formation	Osteoporosis Bone fracture Growth disorders	LOX BMP-3	OPG Collagenase	Collagen
Growth factor Cell cycle Apoptosis	Neurodegenerative disorders Cancer Autoimmunity	c-Kit Bcl-2 GDNF	c-Myc Egr1 Tenascin-c	PCNA Fas Ligand
Hematopoiesis Erythropoiesis	Immune deficiency Thrombocytopenia Anemia	beta-globin c-Mpl	EpoR STAT-1	GpIIb

In Table 2, many genes are associated with multiple activities, but are only listed once. For example, IL-8 could be listed in Angiogenesis and Inflammation; LOX could be listed in Bone formation and Inflammation; and Fas Test compound could be listed in Apoptosis and T-cell activation. A total of 62 distinct genes are represented.

EQUIVALENTS

From the foregoing detailed description of the specific embodiments of the invention, it should be apparent that particular novel compositions and methods involving analysis of novel protein function have been described. Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims that follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made as a matter of routine for a person of ordinary skill in the art to the invention without departing from the spirit and scope of the invention as defined by the claims. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.